Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Sep. 30, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 161,639,208	$ 30,133,213
Accounts receivable	13,422,340	327,375
Prepaid expenses	1,757,928	1,267,717
Other current assets	1,590,195	640,117
Short term investments	56,560,674	46,400,176
TOTAL CURRENT ASSETS	234,970,345	78,768,598
Property and equipment, net	13,378,321	13,935,425
Intangible assets, net	17,913,795	18,764,010
Long term investments	67,536,054
Other assets	141,918	141,918
TOTAL ASSETS	333,940,433	111,609,951
CURRENT LIABILITIES
Accounts payable	4,062,189	2,806,098
Accrued expenses	5,718,774	5,043,087
Accrued payroll and benefits	967,674	3,937,605
Deferred rent	173,952	307,334
Deferred revenue	90,889,801	600
Note Payable		223,820
Other current liabilities		46,407
TOTAL CURRENT LIABILITIES	101,812,390	12,364,951
LONG-TERM LIABILITIES
Deferred rent, net of current portion	1,754,869	1,702,801
Deferred revenue, net of current portion	29,732,938
Note Payable, net of current portion		2,101,198
Other non-current liabilities		200,000
TOTAL LONG-TERM LIABILITIES	31,487,807	4,003,999
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Common stock, $0.001 par value; 145,000,000 shares authorized; 94,665,718 and 88,505,302 shares issued and outstanding as of March 31, 2019 and September 30, 2018, respectively	187,035	180,875
Additional paid-in capital	652,411,876	582,902,694
Accumulated other comprehensive income (loss)	(71,906)	(21,564)
Accumulated deficit	(451,331,581)	(487,265,816)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	201,195,424	95,796,189
Noncontrolling interest	(555,188)	(555,188)
TOTAL STOCKHOLDERS’ EQUITY	200,640,236	95,241,001
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 333,940,433	$ 111,609,951